1103522-80-0
1103522-80-0 structure
- Name: Bavisant dihydrochloride hydrate
- Chemical Name: (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone,hydrate,dihydrochloride
- CAS Number: 1103522-80-0
- Molecular Formula: C19H31Cl2N3O3
- Molecular Weight: 420.37400
- Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
- Create Date: 2017-01-15 23:02:49
- Modify Date: 2024-01-01 20:41:29
-
Bavisant Hcl hydrate(JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. IC50 Value: Target: H3 receptorin vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1].in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1?mg/day, 3?mg/day and 10?mg/day groups, respectively; the change in the 10?mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1?mg/day and 3?mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2
| Name | (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone,hydrate,dihydrochloride |
|---|---|
| Synonyms |
Methanone,(4-cyclopropyl-1-piperazinyl)(4-(4-morpholinylmethyl)phenyl)-,hydrochloride,hydrate (1:2:1)
(4-Cyclopropylpiperazin-1-yl)(4-(morpholin-4-ylmethyl)phenyl)methanone dihydrochloride monohydrate BAVISANT DIHYDROCHLORIDE Bavisant dihydrochloride (USAN) UNII-C1H7H5X3RE Bavisant dihydrochloride hydrate Bavisant (dihydrochloride hydrate) |
| Description | Bavisant Hcl hydrate(JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. IC50 Value: Target: H3 receptorin vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1].in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1?mg/day, 3?mg/day and 10?mg/day groups, respectively; the change in the 10?mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1?mg/day and 3?mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2 |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C19H31Cl2N3O3 |
|---|---|
| Molecular Weight | 420.37400 |
| Exact Mass | 419.17400 |
| PSA | 45.25000 |
| LogP | 2.79240 |
| Storage condition | 2-8℃ |